We examined the incidence, risk factors and associated mortality of acute renal failure requiring dialysis (Renal Bearman Grade [BG] 3) in a 3-year cohort of 97 consecutive allogeneic blood and marrow transplantation (alloBMT) patients. In all, 20 (21%) developed Renal BG3 (all died by day +132) and 77 (79%) developed renal insufficiency (Renal BG1-2). Renal BG3 was a contributing or primary cause of death in 18 (90%) patients who continued to require dialysis at time of death. The two Renal BG3 patients whose deaths were not related to renal failure died on day +103 of hemorrhage and day +132 of underlying disease. By univariate analysis, age, unrelated donor, veno-occlusive disease (VOD) and grade III-IV acute graft-versus-host disease with hepatic involvement were significantly associated with Renal BG3. The multivariate model of time to Renal BG3 determined only a prior diagnosis of severe acute GVHD (RR ¼ 4.1, 95% CI 1.6-10.3, P ¼ 0.003) and VOD (RR ¼ 9.1, 95% CI 3.5-23.7, Po0.001) as significant independent predictors. Renal BG3 is generally considered a conditioning regimen-related toxicity. This study demonstrates that Renal BG3 is most commonly a complication of hepatic co-morbidities after allogeneic blood and marrow transplantation and identifies patients with a very poor prognosis.
Summary:
We examined the incidence, risk factors and associated mortality of acute renal failure requiring dialysis (Renal Bearman Grade [BG] 3) in a 3-year cohort of 97 consecutive allogeneic blood and marrow transplantation (alloBMT) patients. In all, 20 (21%) developed Renal BG3 (all died by day +132) and 77 (79%) developed renal insufficiency (Renal BG1-2). Renal BG3 was a contributing or primary cause of death in 18 (90%) patients who continued to require dialysis at time of death. The two Renal BG3 patients whose deaths were not related to renal failure died on day +103 of hemorrhage and day +132 of underlying disease. By univariate analysis, age, unrelated donor, veno-occlusive disease (VOD) and grade III-IV acute graft-versus-host disease with hepatic involvement were significantly associated with Renal BG3. The multivariate model of time to Renal BG3 determined only a prior diagnosis of severe acute GVHD (RR ¼ 4.1, 95% CI 1.6-10.3, P ¼ 0.003) and VOD (RR ¼ 9.1, 95% CI 3.5-23.7, Po0.001) as significant independent predictors. Renal BG3 is generally considered a conditioning regimen-related toxicity. This study demonstrates that Renal BG3 is most commonly a complication of hepatic co-morbidities after allogeneic blood and marrow transplantation and identifies patients with a very poor prognosis. Bone Marrow Transplantation (2003) 32, 405-410. doi:10.1038/sj.bmt.1704144 Keywords: renal failure; stem cell transplantations; toxicity Allogeneic blood and marrow transplantation (alloBMT) is a major treatment modality for a wide range of malignant and nonmalignant disorders. This procedure is associated with a high risk of treatment-related morbidity and mortality, the latter up to 20% during the early post transplant period.
1 A frequent, life-threatening alloBMT regimen-related toxicity (RRT) is acute renal failure requiring dialysis. Approximately 40% or more of alloBMT patients may develop some degree of acute renal insufficiency, which may progress to renal failure requiring dialysis. 2, 3 Patients are also at higher risk for BMT nephropathy, a disorder similar to hemolytic uremic syndrome, which usually occurs in the chronic phase post-transplant (day +100). 4, 5 The etiology of alloBMT-associated renal failure is usually multifactorial. Risk factors for renal failure requiring dialysis after alloBMT include veno-occlusive disease (VOD), 2,3 age, 2 aminoglycosides, 3 the combined use of amphotericin B and cyclosporine, 6 amphotericin B alone, 7 elevated pre transplant serum creatinine, 3 radiation dose, 8, 9 graft-versus-host disease (GVHD) 9 and cyclosporine. 10, 11 Risk factors after autologous BMT include interstitial nephritis due to ciprofloxacin use. 12 However, there is little information available on the prognosis of patients who develop renal failure requiring dialysis. In this study, we analyzed the incidence, risk factors and associated mortality of acute renal failure requiring dialysis in a cohort of alloBMT patients. We also examined if acute renal failure requiring dialysis was an initiator or sequelae of other transplant-related complications.
Materials and methods
We retrospectively reviewed 97 consecutive adult alloBMT patients at Roswell Park Cancer Institute, Buffalo, NY transplanted between April 1996 and April 1999. We excluded 11 pediatric (o18 years at time of transplant) and two syngeneic alloBMT patients. Renal RRT was classified according to Bearman criteria. 13 Grade 1 consists of an increase in the serum creatinine up to twice the baseline value (Renal BG1), grade 2 is an increase in the serum creatinine of at least twice the baseline level but not requiring dialysis (Renal BG2) and grade 3 is renal failure requiring dialysis (Renal BG3). The decision to dialyze the patient was made by the consulting nephrology service based on the presence of uremic syndrome, severe electrolyte abnormalities and/or volume overload refractory to diuresis in the setting of an elevated serum creatinine and blood urea nitrogen (BUN). 
BMT conditioning regimens

GVHD prophylaxis and treatment
Patients received acute GVHD prophylaxis consisting of cyclosporine (Cs) and methylprednisolone (MP); 18 Cs, methotrexate (Mtx) and MP; 19 Cs, Orthoclone s anti-CD3 monoclonal antibody (OKT3) and MP; 20 Cs and Mtx; 21 Cs, Mp and ATG; Cs, Mtx, Mp and OKT3; Cs, Mp, OKT3 and ATG; Cs alone or tacrolimus (FK506) alone. Cs was switched to FK506 if the patient developed Cs toxicity in 19 of 97 (20%) patients. One patient was scheduled to receive CsMpOKT3 but developed toxicity to both Cs and FK506, which were discontinued and substituted with 2-chlordeoxyadenosine. Acute GVHD up to day 100 was classified according to the published criteria. 22 Acute GVHD Grade II to IV was treated with high-dose MP from 2-10 mg/kg/ day and Cs 2-4 mg/kg/day. Grade I cutaneous GVHD was treated with topical steroids only.
Definition of VOD
VOD was diagnosed based on published criteria, which requires any two of the following within 30 days of BMT: (1) jaundice (bilirubin 41.5 mg/dl) (2) hepatomegaly and right upper quadrant pain (3) ascites and/or unexplained weight gain 45% from baseline. 23 No other identifiable cause for liver disease, including infection or GVHD, could be present.
Supportive care
All patients received antimicrobial prophylaxis with fluconazole (or ketoconazole) and acyclovir. All patients received acyclovir prophylaxis from day 0 to day of discharge for a minimum of 21 days. All patients received VOD prophylaxis either with enoxaparin (n ¼ 62), heparin (n ¼ 17), heparin and alprostadil (n ¼ 17) or none (n ¼ 1). 24 
Statistical analysis
Outcome was dichotomized as renal failure requiring dialysis (Renal BG3) and renal insufficiency not requiring dialysis (Renal BG1-2). Analysis of variance (ANOVA) of independent samples was performed to compare means and w 2 test (with Fisher's exact test, where applicable) was used to compare proportions. The multivariate analysis used a Cox regression model to estimate the association between patient characteristics and time to renal failure requiring dialysis. Patients were censored at time of last follow-up or death if renal failure requiring dialysis did not occur. A forward stepwise conditional model was used based on the likelihood ratio with Po0.05 to enter and P40.1 to remove each variable from the model. Kaplan-Meier survival curves using product limit methods were constructed to estimate the difference in survival between the two groups of renal toxicity. 25 All tests were two sided with a P-value of p0.05 regarded as statistically significant. All analyses were performed using SPSS s version 10.0.5.
Results
Description of Renal BG3 patients
All 97 patients developed at least a grade I renal toxicity as defined by the Bearman criteria (increase in baseline serum creatinine). In all, 19 patients (20%) developed a maximum Renal BG1 toxicity, 58 patients (60%) a maximum Renal BG2 toxicity, 18 patients (19%) a maximum Renal BG3 toxicity and two (2%) a maximum Renal BG4 fatal toxicity. Three of the 20 patients who developed a minimum Renal BG3 toxicity required but did not receive dialysis. These patients had aggressive treatment withdrawn because of severe pre-existing comorbidities. Renal BG3 patients were dialyzed a median 2.5 times (range, 1-14 times, n ¼ 17). In total, 12 (60%) of the Renal BG3 patients also received mechanical ventilation which was initiated before (n ¼ 4), on the same day (n ¼ 3) or after (n ¼ 5) the diagnosis of Renal BG3. In comparison, 14 (18%) of the Renal BG1-2 patients received mechanical ventilation anytime before day +100 post BMT (Po0.001).
In all, 10 (50%) of the 20 patients with Renal BG3 developed grade III-IV acute GVHD prior to initiation of dialysis. Four of these patients had skin and liver involvement; six had skin, liver and GI involvement. All 10 of these patients had a normal baseline serum bilirubin (median 0.7 mg/dl, range 0.3-1.2). However, they developed hyperbilirubinemia (median 40.5 mg/dl, range 6.4-54.4) because of severe acute GVHD with hepatic involvement, and were subsequently diagnosed with Renal BG3. Eight patients developed hyperbilirubinemia (median 17.9 mg/dl, range 5.5-54) because of severe hepatic VOD (three of whom also had severe acute GVHD) and were subsequently diagnosed with Renal BG3. In total, 15 (75%) of the patients who developed Renal BG3 were previously diagnosed with hepatic VOD and/or severe acute GVHD with hepatic involvement. Only five (25%) patients As part of GVHD prophylaxis (three to four doses on days +1, +3 and +6 for related donors and additionally day +11 for unrelated BM and PBSC donors).
developed Renal BG3 without a severe hepatic comorbidity (median bilirubin 2.1 mg/dl, range 0.9-3.5).
Since fluid management was included in the definition of renal failure requiring dialysis, we examined serum creatinine level at time of Renal BG3 diagnosis to compare renal function as criteria for dialysis. The five patients without VOD or severe acute GVHD were dialyzed with a median creatinine of 4.5 mg/dl, range 2.0-8.4. The eight patients with VOD were dialyzed with a median creatinine of 4.5 mg/dl, range 2.4-6.6. The 10 patients with severe acute GVHD were dialyzed with a median creatinine of 4.7 mg/dl, range 3.0-7.5.
Univariate analysis of risk factors for Renal BG3 Table 1 summarizes the univariate analysis of patient characteristics and Renal BG3. Factors significantly associated with Renal BG3 renal toxicity in the univariate analysis included age at BMT (P ¼ 0.009), unrelated donor (P ¼ 0.04), diagnosis of VOD that preceded onset of Renal BG3 (Po0.001) and diagnosis of grade III-IV acute GVHD prior to Renal BG3 (P ¼ 0.009). The serum bilirubin level at the time of doubling of serum creatinine was not associated with renal failure, hence serum bilirubin alone cannot be considered a predictive marker of Renal BG3. In addition, age was stratified by decade and baseline creatinine was found to increase with age (P ¼ 0.022, Table 2 ).
Multivariate analysis of risk factors for Renal BG3
All factors that were statistically significant in the univariate analysis were selected for consideration in the multivariate model. Table 3 summarizes the independent predictors of time to developing Renal BG3 determined by multivariate analysis using forward stepwise regression: a diagnosis of grade III-IV acute GVHD that preceded Renal BG3 (RR ¼ 4.1, 95% CI 1.6-10.3, P ¼ 0.003) and a diagnosis of VOD that preceded Renal BG3 (RR ¼ 9.1, 95% CI 3.5-23.7, Po0.001).
Survival analysis
Median follow-up for all surviving transplant patients was 45 months (range 1-70 months). By day 100, overall survival for those with Renal BG1-2 was 82% compared to 10% for Renal BG3 (Po0.001, see Figure 1 ). By day 132, all patients with Renal BG3 had died. For the Renal BG3 patients, renal failure was the primary cause of death in two patients, a contributing cause of death in 16 patients and not related to death in two patients (see Table 4 ). The two patients, whose deaths were unrelated to renal failure, died of hemorrhage on day +103 and disease on day +132 and were the only two patients who survived past day 100. Renal BG3 patients died a median 5 days (range, 1-98 days) after being diagnosed with renal failure requiring dialysis. Figure 2 depicts the probability of developing Renal BG3 by overall grade of acute GVHD. Patients with an overall grade III-IV acute GVHD had a 45% probability of Table 2 Baseline creatinine by decade of age at BMT Table 3 Multivariate analysis of independent factors predicting renal failure requiring dialysis (25) 5 (25) a One patient in the Renal BG1-2 group with acute lymphoblastic leukemia died of a leukemia/lymphoproliferative disorder of uncertain etiology, GVHD: graft-versus-host disease; RRT: regimen-related toxicity.
developing Renal BG3 by day 100 compared to a 15% probability for patients with overall grade 0-II acute GVHD (P ¼ 0.0086). Similarly, patients who developed VOD had a 64% probability of developing Renal BG3 by day 100 compared to a 16% probability for patients who did not develop VOD (Po0.0001, Figure 3 ).
Discussion
The purpose of this study was to examine the incidence, risk factors and associated mortality of acute renal failure requiring dialysis. Development of Renal BG3 had a significant impact on survival since mortality was 100% by day 132 in this group of patients. Other studies have also mentioned a similar high mortality rate in patients with renal failure requiring dialysis.
2,3
In this study, VOD and severe acute GVHD were significantly associated with Renal BG3 in both the univariate and multivariate analyses. The higher incidence of renal failure in VOD patients may be due to renal tubular damage and the associated multiorgan failure that occurs with severe VOD. 13, 26 Severe to fatal acute GVHD usually represents systemic damage to more than one organ system. All patients who developed acute renal failure requiring dialysis with concomitant grade III-IV acute GVHD had at least skin and hepatic involvement. The hepatic insufficiency of severe acute GVHD likely predisposes these patients to the hepato-renal syndrome that complicates severe liver disease.
Other significant associations in the univariate analysis included age at time of transplant and use of an unrelated donor graft. Decreased renal function with advanced age and associated comorbidities may be responsible for a higher incidence of Renal BG3 with advanced age. Unrelated donor transplants use more intensive myeloablative regimens and GVHD prophylaxis regimens, both of which can be nephrotoxic and immunosuppressive. They are also associated with higher rates of fungal infections, which are usually treated with nephrotoxic drugs (ie, amphotericin B).
We demonstrated that renal failure requiring dialysis is usually a complication of other hepatic comorbidities (ie, severe acute GVHD and VOD). Strategies to control the incidence and severity of acute GVHD and VOD will likely decrease Renal BG3. Once diagnosed with acute renal failure requiring dialysis, patients have a high probability of death within a median of less than 1 week. This poor prognosis may influence patient and physician decisions regarding end-of-life care. The difference between the groups is statistically significant (P ¼ 0.0086). Tick marks indicate patients who were censored alive at last follow-up or at time of death without acute renal failure. The graph is truncated at 175 days, but the plateaus for both curves continue past day +2000 post transplant. Figure 3 Kaplan-Meier curves depicting the probability of developing acute renal failure requiring dialysis by presence or absence hepatic venoocclusive disease. Solid line indicates patients who developed hepatic venoocclusive disease before the onset of acute renal failure requiring dialysis; the dashed line indicates those patients who did not develop hepatic venoocclusive disease before onset of acute renal failure requiring dialysis. The difference between the groups is statistically significant (Po0.0001). Tick marks indicate patients who were censored alive at last follow-up or at time of death without acute renal failure. The graph is truncated at 175 days, but the plateaus for both curves continue past day +2000 post transplant.
